COL19A1 and amyotrophic lateral sclerosis: The linear mixed model analysis showed that ALS patients that exhibited high COL19A1 levels from symptom onset also progressed faster during the follow-up period of 24 months from symptom onset (Estimate: -0,0093, CI: (-0,0181) - (-0,00039); P =0,042) (Fig. 4A).